Advertisement


Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials

2017 ESMO Congress

Advertisement

Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma treatment; the ARIEL3 study on rucaparib vs placebo in recurrent ovarian carcinoma; and the ENGOT-OV16/NOVA on quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstracts 929O, LBA40, 930O).



Related Videos

Prostate Cancer

Cora N. Sternberg, MD, on Prostate Cancer Treatment Findings: Expert Perspective

Cora N. Sternberg, MD, of the San Camillo Forlanini Hospital, summarizes a session on the STAMPEDE and LATITUDE trials, as well as a third trial on docetaxel with androgen suppression for localized prostate cancer patients who relapsed after radical prostatectomy and/or radiotherapy (Abstracts LBA31, 783O, 784O).

Kidney Cancer

Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial

Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups (Abstract LBA5).

Kidney Cancer

Bernard J. Escudier, MD, on RCC: Expert Perspective on Key Papers

Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors

Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K were discussed.

Skin Cancer

Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial

Karl D. Lewis, MD, of the Anschutz Cancer Pavilion, discusses study findings on adjuvant vemurafenib in patients with completely resected BRAF V600–positive melanoma at high risk for recurrence (Abstract LBA7).

Advertisement

Advertisement




Advertisement